For the quarter ending 2026-03-31, ABEO made $8,720K in revenue. -$17,234K in net income. Net profit margin of -197.64%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Product revenue, net | 8,720 | 4,620* | - | 400 |
| Cost of sales | 2,696 | 68* | 488 | - |
| Royalties | - | 1,593* | - | 100 |
| Research and development | 9,555 | 6,712 | 4,216 | 5,943 |
| Selling, general and administrative | 19,502 | 19,158* | 19,314 | 17,149 |
| Total expenses | - | - | - | 23,192 |
| Total costs and expenses | 31,753 | 27,531* | 24,018 | - |
| Loss from operations | -23,033 | -22,911 | -24,018 | -22,792 |
| Interest income | 1,354 | 1,547 | 1,672 | 1,027 |
| Interest expense | 830 | 884 | 901 | 957 |
| Change in fair value of warrant liabilities | -5,386 | -1,522 | -2,760 | 5,388 |
| Loss from sale of priority review voucher, net | - | -157 | - | 152,366 |
| Other income, net | 50 | 51 | 129 | 89 |
| Gain before income taxes | -17,073 | -20,832* | -20,358 | 124,345 |
| Income tax expense | 2 | -372* | -15,197 | 15,512 |
| Net gain | -17,075 | -20,460 | -5,161 | 108,833 |
| Change in unrealized losses related to available-for-sale debt securities | -159 | 128 | 55 | 22 |
| Comprehensive gain | -17,234 | -20,332 | -5,106 | 108,855 |
| Basic EPS | -0.3 | -0.368 | -0.1 | 2.07 |
| Diluted EPS | -0.3 | -0.217 | -0.1 | 1.71 |
| Basic Average Shares | 56,620,920 | 55,265,850 | 54,242,507 | 52,524,510 |
| Diluted Average Shares | 56,620,920 | 93,881,356 | 54,242,507 | 66,640,620 |
ABEONA THERAPEUTICS INC. (ABEO)
ABEONA THERAPEUTICS INC. (ABEO)